Erschienen:
American Association for Cancer Research (AACR), 2004
Erschienen in:
Clinical Cancer Research, 10 (2004) 8, Seite 2600-2608
Sprache:
Englisch
DOI:
10.1158/1078-0432.ccr-03-0239
ISSN:
1078-0432;
1557-3265
Entstehung:
Anmerkungen:
Beschreibung:
Abstract Purpose: While naïve T cells circulate between peripheral blood and lymph nodes, memory effector T cells acquire certain surface molecules that enable them to travel to peripheral tissues and exert their effector function. We analyzed whether deficient numbers of effector-type T cells within the malignant effusion might contribute to tumor escape from immunosurveillance. Experimental Design: We analyzed the expression of a broad range of adhesion molecules and chemokine receptors (CD62L, CD56, CCR4, CCR5, CCR7, CXCR3, CLA, and integrin α4β7) on tumor-associated lymphocytes in effusions and peripheral blood lymphocytes of patients with malignant ascites (n = 11) or malignant pleural effusion (n = 16). A tumor-associated lymphocyte:peripheral blood lymphocyte ratio was calculated as an indicator for homing of lymphocytes into the effusions and was compared with patients with nonmalignant ascites (n = 17). Results: Patients with malignancies show an increased enrichment of T cells expressing the phenotype of “naïve” (CD62L+ and CD45RA+CCR7+), “central memory” (CD45RA-CCR7+), and type 2-polarized (CCR4+) T cells within their effusions. In contrast, enrichment of “effector”-type (CD45RA-CCR7− or CD45RA+CCR7−) and presumably type 1-polarized T cells (CCR5+) at the tumor site is deficient. The same is true for natural killer cells and potentially cytotoxic CD56+ T cells. Conclusions: Here we show for the first time that patients with malignant effusions show a deficient enrichment of T cells expressing the phenotype of type-1-polarized effector T cells at the tumor site. This mechanism is likely to contribute to the escape of tumor cells from immunosurveillance.